Table 3.
Multivariate analyses of prognostic factors correlated with OS in MTM and non-MTM HCC
| Variables | Whole population | MTM | Non-MTM | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Overall survival | ||||||
| Gender (male vs. female) | 0.616 (0.379–1.000) | 0.050 | ||||
| AFP (ng/ml) (< 20 vs. ≥ 20) | 1.016 (0.825–1.251) | 0.883 | ||||
| Tumor multiplicity (single vs. multiple) | 1.361 (1.110–1.669) | 0.003 | 1.672 (1.232–2.269) | 0.001 | 1.197 (0.906–1.582) | 0.205 |
| Tumor size (cm) (< 5 vs. ≥ 5) | 1.414 (1.127–1.773) | 0.003 | 1.427 (1.020–1.996) | 0.038 | 1.446 (1.041–2.008) | 0.028 |
| Differentiation (well vs. moderate–poor) | 1.275 (0.939–1.730) | 0.119 | 1.298 (0.868–1.941) | 0.204 | ||
| TNM stage (I–II vs. III–IV) | 1.114 (0.888–1.398) | 0.350 | 1.061 (0.743–1.514) | 0.747 | 1.163 (0.861–1.572) | 0.325 |
| Vascular invasion (no vs. yes) | 1.742 (1.347–2.253) | 0.000 | 2.246 (1.452–3.474) | 0.000 | 1.557 (1.130–2.128) | 0.005 |
| Tumor capsule (complete vs. incomplete) | 0.916 (0.759–1.105) | 0.359 | 0.785 (0.597–1.032) | 0.083 | ||
| LN metastasis (no vs. yes) | 2.032 (1.384–2.984) | 0.000 | 4.049 (2.328–7.044) | 0.000 | 1.446 (0.827–2.425) | 0.205 |
| Tumoral PD-L1 (− vs. +) | 1.167 (0.973–1.400) | 0.097 | 1.384 (0.994–1.928) | 0.054 | ||
| Inflammatory cell PD-L1 (− vs. +) | 1.384 (0.883–1.676) | 0.231 | ||||
| CMTM6 expression (low vs. high) | 1.056 (1.005–1.109) | 0.030 | 1.116 (0.850–1.464) | 0.430 | 1.280 (0.994–1.647) | 0.055 |
AFP a-fetoprotein, HBV hepatitis B virus infection, LN lymph node, HR hazard ratio, CI confidence interval
*P value < 0.05 in bold are statistically significant
aMedian age; bMedian tumor size